Duality Advisers LP Acquires 2,253 Shares of Eli Lilly and Company (NYSE:LLY)

Duality Advisers LP raised its position in Eli Lilly and Company (NYSE:LLY - Free Report) by 26.4% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 10,774 shares of the company's stock after buying an additional 2,253 shares during the period. Eli Lilly and Company accounts for about 0.7% of Duality Advisers LP's investment portfolio, making the stock its 10th biggest position. Duality Advisers LP's holdings in Eli Lilly and Company were worth $6,280,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in LLY. Vanguard Group Inc. raised its stake in shares of Eli Lilly and Company by 0.9% in the third quarter. Vanguard Group Inc. now owns 70,575,602 shares of the company's stock worth $37,908,273,000 after acquiring an additional 659,838 shares during the last quarter. Morgan Stanley raised its stake in shares of Eli Lilly and Company by 0.7% in the third quarter. Morgan Stanley now owns 12,545,572 shares of the company's stock worth $6,738,605,000 after acquiring an additional 83,915 shares during the last quarter. Northern Trust Corp raised its stake in shares of Eli Lilly and Company by 3.6% in the third quarter. Northern Trust Corp now owns 10,158,275 shares of the company's stock worth $5,456,314,000 after acquiring an additional 355,317 shares during the last quarter. Norges Bank bought a new stake in shares of Eli Lilly and Company during the fourth quarter worth approximately $3,416,206,000. Finally, International Assets Investment Management LLC raised its stake in shares of Eli Lilly and Company by 61,268.8% during the fourth quarter. International Assets Investment Management LLC now owns 7,342,780 shares of the company's stock worth $42,802,530,000 after buying an additional 7,330,815 shares during the last quarter. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Eli Lilly and Company Price Performance

Eli Lilly and Company stock traded down $19.64 during trading hours on Friday, reaching $726.31. 3,505,526 shares of the stock were exchanged, compared to its average volume of 2,202,924. The company has a market cap of $690.11 billion, a P/E ratio of 125.23, a price-to-earnings-growth ratio of 1.58 and a beta of 0.34. The company has a current ratio of 0.94, a quick ratio of 0.73 and a debt-to-equity ratio of 1.69. Eli Lilly and Company has a twelve month low of $369.76 and a twelve month high of $800.78. The stock has a 50 day moving average of $763.96 and a two-hundred day moving average of $661.44.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its quarterly earnings data on Tuesday, February 6th. The company reported $2.49 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.30 by $0.19. The firm had revenue of $9.35 billion for the quarter, compared to the consensus estimate of $8.95 billion. Eli Lilly and Company had a net margin of 15.36% and a return on equity of 51.22%. The business's revenue for the quarter was up 28.1% on a year-over-year basis. During the same period in the prior year, the company posted $2.09 earnings per share. Equities analysts expect that Eli Lilly and Company will post 12.52 EPS for the current fiscal year.

Insider Activity

In related news, major shareholder Lilly Endowment Inc sold 78,573 shares of Eli Lilly and Company stock in a transaction that occurred on Wednesday, January 31st. The shares were sold at an average price of $648.07, for a total transaction of $50,920,804.11. Following the sale, the insider now directly owns 99,333,810 shares in the company, valued at approximately $64,375,262,246.70. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. 0.13% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

A number of research firms recently weighed in on LLY. BMO Capital Markets boosted their price target on shares of Eli Lilly and Company from $710.00 to $865.00 and gave the stock an "outperform" rating in a research note on Wednesday, February 7th. Citigroup boosted their price target on shares of Eli Lilly and Company from $675.00 to $895.00 and gave the stock a "buy" rating in a research note on Tuesday, April 2nd. JPMorgan Chase & Co. upped their target price on shares of Eli Lilly and Company from $775.00 to $850.00 and gave the company an "overweight" rating in a research note on Friday, March 15th. Morgan Stanley upped their target price on shares of Eli Lilly and Company from $805.00 to $950.00 and gave the company an "overweight" rating in a research note on Friday, February 16th. Finally, TheStreet raised shares of Eli Lilly and Company from a "c+" rating to a "b" rating in a research note on Friday, March 8th. Three analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company's stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $728.05.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.